J&J Settles Pfizer's Antitrust Suit Over Remicade Biosimilar
Pfizer Inc. has agreed to drop its four-year-old suit alleging Johnson & Johnson violated antitrust laws by coercing health insurers into not covering biosimilar versions of J&J's inflammatory disease biologic Remicade,...To view the full article, register now.
Already a subscriber? Click here to view full article